menopause meds

Question 1

hormone replacement therapy considerations

Answer 1

increased risk of breast cancer
progestrone needed 12 days/month if pt has a uterus
taper to prevent withdrawal
wide range of formulations

Question 2

clonidine MOA

Answer 2

centrally acting alpha 2 agonist

Question 3

clonidine indication

Answer 3

reduce hot flashes

Question 4

clonidine AE

Answer 4

dry mouth, somnolence, dizziness, AV block

interactions with meds - HTN

Question 5

clonidine dosing

Answer 5

0.1-0.2 mg PO QD or 0.1 mg patch weekly

Question 6

osempifine indication

Answer 6

treat dyspareuia

Question 7

osempifine MOA

Answer 7

selectjive estrogen receptor modulator

decreases vaginal pH

Question 8

osempifine AE

Answer 8

hot flashes, vaginal discharge, muscle spasm, hiperhydrosis

caution w hx of DVT/PE
contraindicated in endometrial CA

Question 9

osempifine dosing

Answer 9

60 mg QD w food

Question 10

paroxetine MOA

Answer 10

SSRI

Question 11

paroxetine indication

Answer 11

reduction in hot flashes

Question 12

paroxetine AE

Answer 12

suicide, SJS, serotonin syndrome, risk of fractures, GI, dry mouth, fatigue, seizures

slow withdrawal

CYP2D6 inhibitor - tamoxifen, warfarin, digoxin, theophylline interactions

Question 13

paroxetine dosing

Answer 13

7.5 mg PO QHS

Question 14

venlafaxine MOA

Answer 14

inhibits serotonin, norepi, and DA reuptake

Question 15

venlafaxine indication

Answer 15

reduction in hot flashes

Question 16

velnafaxine AE

Answer 16

suicidality, HTN, HA, sweating, GI, dry mouth, serotonin syndrome

slow withdrawal

do not take w MAOIs

Question 17

gabapentin indication

Answer 17

reduction in hot flashes